I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Development of Potent Dual BET/HDAC Inhibitors via Pharmaco..:
Nicolas Bauer
;
Dimitrios-Ilias Balourdas
;
Joel R. Schneider
...
doi:10.1021/acschembio.3c00427.s001. , 2024
Link:
https://doi.org/10.1021/acschembio.3c00427.s001
RT Journal T1
Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization
UL https://suche.suub.uni-bremen.de/peid=base-ftdeakinunifig:oai:figshare.com:article_25117159&Exemplar=1&LAN=DE A1 Nicolas Bauer A1 Dimitrios-Ilias Balourdas A1 Joel R. Schneider A1 Xin Zhang A1 Lena M. Berger A1 Benedict-Tilman Berger A1 Martin P. Schwalm A1 Nick A. Klopp A1 Jens T. Siveke A1 Stefan Knapp A1 Andreas C. Joerger YR 2024 K1 Biochemistry K1 Molecular Biology K1 Pharmacology K1 Cancer K1 Biological Sciences not elsewhere classified K1 Chemical Sciences not elsewhere classified K1 target activity translated K1 nut midline carcinoma K1 future translational studies K1 could also show K1 choosing starting scaffolds K1 100 nm range K1 guided optimization bromodomain K1 different cancer models K1 pancreatic cancer cells K1 potent dual bet K1 available dual bet K1 50 </ sub K1 pancreatic cancer K1 dual bet K1 guided modification K1 cancer therapy K1 tp63 </ K1 p57 </ K1 myc </ K1 hexim1 </ K1 bet inhibition K1 two functionalities K1 tumor suppressor K1 treat tumors K1 terminal domain K1 study expands K1 single compound K1 series binding K1 selective inhibition K1 recent research K1 promising efficacy K1 prime targets K1 particularly focused K1 parent compounds K1 optimized binders K1 optimally merge K1 oncogenic drivers K1 new series K1 mrna levels K1 lead molecules K1 histone deacetylases K1 hdac inhibitors K1 enabled us K1 brd4 bromodomains JF doi:10.1021/acschembio.3c00427.s001 LK http://dx.doi.org/https://doi.org/10.1021/acschembio.3c00427.s001 DO https://doi.org/10.1021/acschembio.3c00427.s001 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)